The European Medicines Agency has accepted and will review the marketing authorization application for Roclanda, Aerie Pharmaceuticals announced in a press release.
Roclanda (netarsudil and latanoprost ophthalmic solution 0.02%/0.005%), marketed as Rocklatan in the Unites States, is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
“We are delighted that the European regulatory authorities have accepted our Roclanda filing for review. If approved, Roclanda, the combination of our Rho kinase inhibitor with a prostaglandin analog, would be the
Uncategorized